MilliporeSigma
  • Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.

Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.

Cancer letters (2014-03-26)
Zhiyu Chen, Veena Sangwan, Sulagna Banerjee, Rohit Chugh, Vikas Dudeja, Selwyn M Vickers, Ashok K Saluja
ABSTRACT

The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) causes cancer cell death, but many cancers, including pancreatic cancer, are resistant to TRAIL therapy. A combination of TRAIL and the diterpene triepoxide, triptolide, is effective in inducing pancreatic cancer cell death. Triptolide increases levels of death receptor DR5 and decreases the pro-survival FLICE-like inhibitory protein (c-FLIP), which contribute to the activation of caspase-8. This combination further causes both lysosomal and mitochondrial membrane permeabilization, resulting in cell death. Our study provides a mechanism by which triptolide sensitizes TRAIL resistant cells, which may become a novel therapeutic strategy against pancreatic cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Cathepsin B (Ab-1) Mouse mAb (CA10), lyophilized, clone CA10, Calbiochem®